SUJAY KANGO - 27 Sep 2021 Form 4 Insider Report for ACCELERON PHARMA INC

Role
EVP, Chief Commercial Officer
Signature
/s/ Adam M. Veness, as attorney-in-fact for Sujay Kango
Issuer symbol
N/A
Transactions as of
27 Sep 2021
Net transactions value
-$671,950
Form type
4
Filing time
27 Sep 2021, 19:21:31 UTC
Previous filing
22 Sep 2021
Next filing
22 Nov 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XLRN Common Stock Options Exercise $203,050 +5,000 +27% $40.61 23,509 27 Sep 2021 Direct F1
transaction XLRN Common Stock Sale $875,000 -5,000 -21% $175.00 18,509 27 Sep 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction XLRN Option to Purchase Common Stock Options Exercise $0 -5,000 -17% $0.000000 25,000 27 Sep 2021 Common Stock 5,000 $40.61 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2 The shares of common stock underlying this stock option award vested as to 25% of the shares on the first anniversary of February 12, 2018 and the remaining shares vest in equal quarterly installments over the following three years thereafter.